Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab

被引：28

作者：

Senoo, Satoru ^{[1
]}

Ninomiya, Takashi ^{[1
]}

Makimoto, Go ^{[1
]}

Nishii, Kazuya ^{[1
]}

Kano, Hirohisa ^{[1
]}

Watanabe, Hiromi ^{[1
]}

Hata, Yusuke ^{[1
,2
]}

Kubo, Toshio ^{[1
]}

Tanaka, Takehiro ^{[3
]}

Hotta, Katsuyuki ^{[4
]}

Maeda, Yoshinobu ^{[5
]}

Kiura, Katsuyuki ^{[1
]}

机构：

[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan

[2] Kure Kyosai Hosp, Dept Resp Med, Kure, Japan

[3] Okayama Univ Hosp, Div Diagnost Pathol, Okayama, Japan

[4] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan

[5] Okayama Univ, Dept Hematol Oncol & Resp Med, Grad Sch Med Dent & Pharmaceut Sci, Okayama, Japan

来源：

INTERNAL MEDICINE | 2019年 / 58卷 / 07期

基金：

日本学术振兴会;

关键词：

pulmonary pleomorphic carcinoma; immune checkpoint inhibitor; PD-1; PD-L1; FGFR; PALLIATIVE CHEMOTHERAPY; PEMBROLIZUMAB; CELLS;

D O I：

10.2169/internalmedicine.0890-18

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Pulmonary pleomorphic carcinoma (PPC) is a rare very aggressive subtype of non-small cell lung cancer. We herein report a case of PPC that showed a rapid response to nivolumab. The patient, whose multiple tumors had progressed very aggressively, was treated with nivolumab, an anti-programmed cell death-1 (PD-1) antibody. The tumors dramatically shrank after one cycle of nivolumab. The tumors were positive for programmed cell death ligand 1 (PD-L1). An immunohistochemical analysis revealed numerous PD-1(+), CD68(+) and CD206(+) macrophages. This PD-1 antibody may be a good treatment option, especially in tumors that express PD-L1 and which show PD-1(+) macrophage infiltration.

引用

页码：985 / 989

页数：5

共 15 条

[1] Palliative chemotherapy for pulmonary pleomorphic carcinoma [J].

Bae, Hyun-Mi ;

Min, Hye Sook ;

Lee, Se-Hoon ;

Kim, Dong-Wan ;

Chung, Doo Hyun ;

Lee, Jong-Seok ;

Kim, Young Whan ;

Heo, Dae Seog .

LUNG CANCER, 2007, 58 (01) :112-115

[2] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[3] Pulmonary pleomorphic (spindle) cell carcinoma: peculiar clinicopathologic manifestations different from ordinary non-small cell carcinoma [J].

Cheng, YL ;

Lee, YC ;

Shih, JY ;

Wu, CT .

LUNG CANCER, 2001, 34 (01) :91-97

[4] PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity [J].

Gordon, Sydney R. ;

Aute, Roy L. M. ;

Dulken, Ben W. ;

Hutter, Gregor ;

George, Benson M. . ;

Ccracken, Melissa N. M. ;

Gupta, Rohit ;

Tsai, Jonathan M. . ;

Sinha, Rahul ;

Corey, Daniel ;

Ring, Aaron M. . ;

Connolly, Andrew J. ;

Weissman, Irving L. .

NATURE, 2017, 545 (7655) :495-+

[5] Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer [J].

Holdman, Xue B. ;

Welte, Thomas ;

Rajapakshe, Kimal ;

Pond, Adam ;

Coarfa, Cristian ;

Mo, Qianxing ;

Huang, Shixia ;

Hilsenbeck, Susan G. ;

Edwards, Dean P. ;

Zhang, Xiang ;

Rosen, Jeffrey M. .

BREAST CANCER RESEARCH, 2015, 17

[6] The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma [J].

Hong, Jung Yong ;

Choi, Moon Ki ;

Uhm, Ji Eun ;

Park, Min Jae ;

Lee, Jeeyun ;

Park, Yeon Hee ;

Ahn, Jin Seok ;

Park, Keunchil ;

Han, Joung Ho ;

Ahn, Myung Ju .

MEDICAL ONCOLOGY, 2009, 26 (03) :287-291

[7] Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1 [J].

Ikematsu, Yuki ;

Yoneshima, Yasuto ;

Ijichi, Kayo ;

Tanaka, Kentaro ;

Harada, Taishi ;

Oda, Yoshinao ;

Nakanishi, Yoichi ;

Okamoto, Isamu .

LUNG CANCER, 2017, 112 :230-231

[8] "Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy [J].

Ito, Kentaro ;

Hataji, Osamu ;

Katsuta, Koji ;

Kobayashi, Tetsu ;

Gabazza, Esteban C. ;

Yatabe, Yasushi ;

Taguchi, Osamu ;

Yamamoto, Nobuyuki .

JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) :E117-+

[9] Case series of pleomorphic carcinomas of the lung treated with nivolumab [J].

Kanazu, Masaki ;

Uenami, Takeshi ;

Yano, Yukihiro ;

Nakatsubo, Saeko ;

Hosono, Yuki ;

Ishijima, Mikako ;

Akazawa, Yuki ;

Yamaguchi, Toshihiko ;

Urasaki, Koji ;

Mori, Masahide ;

Yokota, Soichiro .

THORACIC CANCER, 2017, 8 (06) :724-728

[10] Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas [J].

Kim, Sehui ;

Kim, Moon-Young ;

Koh, Jaemoon ;

Go, Heounjeong ;

Lee, Dong Soo ;

Jeon, Yoon Kyung ;

Chung, Doo Hyun .

EUROPEAN JOURNAL OF CANCER, 2015, 51 (17) :2698-2707

← 1 2 →